On Wednesday, Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in adults with HIV-1 infection that is virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamidei (BIC/FTC/TAF) in trial MK-8591A-052) or antiretroviral therapy (bART) in trial MK-8591A-051.
In both trials, DOR/ISL met the primary efficacy success criterion for non-inferiority to comparator antiretroviral therapies and primary safety objectives at Week 48.
The company released the topline data from both studies in December 2024.
Also Read: Merck Injects $1 Billion To Expand Vaccine Production In US
Merck plans to begin submitting applications for marketing authorization to regulatory agencies by mid-2025.
- In the trial MK-8591A-052, results for the primary endpoint (HIV-1 RNA ≥50 copies/mL) showed that 1.5% of participants who switched to DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 0.6% on BIC/FTC/TAF.
- At Week 48, 91.5% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA <50 copies/mL) compared to 94.2% of participants who continued receiving BIC/FTC/TAF.
In the trial MK-8591A-051, results for the primary endpoint showed that 1.4% of participants who received DOR/ISL had a viral load of ≥50 copies/mL at Week 48, compared to 4.9% on bART.
- At Week 48, 95.6% of participants who switched to DOR/ISL maintained viral suppression (HIV-1 RNA <50 copies/mL) compared to 91.9% of participants who continued on bART.
Price Action: MRK stock is down 0.65% at $94.11 at the last check Wednesday.
Read Next:
- Arcos Dorados Q4 Earnings: Sales Slip, EPS Beat, South Latin America Strength And More
Photo Courtesy of Merck
